Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | IDO1 | P14902 | 1/20 | 0.56 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.55 |
| ▸ | HTR3B | O95264 | 2/20 | 0.55 |
| ▸ | HTR3A | P46098 | 2/20 | 0.55 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.55 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15527640 | 0.98 | MEN1 (0.62) | MEN1KMT2ALMNAMAPTHTT | |
| SCHEMBL14449056 | 0.92 | MEN1 (0.56) | MEN1KMT2ALMNAMAPTHTT | |
| SCHEMBL13584733 | 0.92 | MEN1 (0.60) | MEN1KMT2ALMNAMAPTHTT | |
| SCHEMBL29518687 | 0.92 | MEN1 (0.60) | MEN1KMT2ALMNAMAPTHTT | |
| Hydrochloric Acid SCHEMBL13584417 | 0.90 | MEN1 (0.58) | MEN1KMT2ALMNAMAPTHTT | |
| SCHEMBL14448339 | 0.86 | NPC1 (0.58) | MEN1KMT2ALMNAMAPTHTT | |
| SCHEMBL1229884 | 0.85 | HTR3E (0.54) | MEN1KMT2ALMNAMAPTHTT | |
| SCHEMBL4682287 | 0.84 | KMT2A (0.51) | MEN1KMT2ALMNAMAPTHTT | |
| Hydrochloric Acid SCHEMBL1320574 | 0.84 | HTR3E (0.53) | MEN1KMT2ALMNAMAPTHTT | |
| SCHEMBL10783714 | 0.83 | MEN1 (0.60) | MEN1KMT2ALMNAMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150051291-A1 | N,N'-DI-1 NAPHTHYLGUANIDINE HCL (NAGH) AND N,N'-DI-P-NITROPHENYLGUANIDINE HCL (NAD) TREATMENT FOR STROKE AT DELAYED TIMEPOINTS | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-02-19 | — | — | US | claimed |
| US-20110201688-A1 | N,N'-DI-P-BROMOPHENYL GUANIDINE TREATMENT FOR STROKE AT DELAYED TIMEPOINTS | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-08-18 | — | — | US | claimed |
| US-20070203140-A1 | N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase | INCYTE CORPORATION | 2007-08-30 | — | — | US | disclosed |
| WO-2007095050-A2 | N-HYDROXYGUANIDINES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2007-08-23 | — | — | WO | disclosed |
| US-4828957-A | Two-color heat-sensitive recording material with 2-hydroxy-3-naphthoanilide as both coupler and color developing agent | KANZAKI PAPER MANUFACTURING COMPANY, LTD. (JP) | 1989-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051291-A1 | N,N'-DI-1 NAPHTHYLGUANIDINE HCL (NAGH) AND N,N'-DI-P-NITROPHENYLGUANIDINE HCL (NAD) TREATMENT FOR STROKE AT DELAYED TIMEPOINTS | DCX, DBH, CHRNA9 | MEN1 4327/4885KMT2A 1965/4885LMNA 862/4885 |
| US-20070203140-A1 | N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase | IDO1, IDO2, HNMT | MEN1 2842/4885KMT2A 882/4885LMNA 4617/4885 |
| US-20110201688-A1 | N,N'-DI-P-BROMOPHENYL GUANIDINE TREATMENT FOR STROKE AT DELAYED TIMEPOINTS | SIGMAR1, TMEM97, HYOU1 | MEN1 4804/4885KMT2A 2934/4885LMNA 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.